Sars cov 2 Antigen Rapid Test Kit

Effectivity Traits

JOYSBIO’s coronavirus Ag check out gear was independently evaluated at Centro Diagnostico Delta S.r.l. in Italy between October 2020 and January 2021. An entire of 107 constructive specimens had been examined with JOYSBIO’s COVID-19 Antigen Speedy Verify Tools. These specimens had been collected from victims who’re suspected of COVID-19 with nasal swabs. The coronavirus antigen check out gear’s sensitivity and specificity are in distinction in the direction of a CE-IVD marked RT-PCR check out gear. This medical evaluation is carried out beneath the concept SARS-CoV just isn’t spreading domestically. 

Primarily based on the medical analysis of 492 samples, the detection sensitivity is 98.13%, and the specificity is 99.22%.

• Constructive % Settlement (PPA) = 105/107 (98.13%) (95%CI: 93.4%~99.8%)
• Adversarial % Settlement (NPA) = 382/385 (99.22%) (95%CI:97.7%~99.8%)
• Accuracy = (105+382)/492×100%=98.98%
• Kappa = 2×(105×382-3×2)/(108×385+107 ×384) = 0.97＞0.5

The limit of detection (LOD) of this product is 1.6 x 10² TCID₅₀/mL, calculated by way of a gradient dilution methodology.

Please Observe:

 Beneath listed kits are validated with the talked about batch amount solely. Responsibility for batch to batch consistency would not lies with ICMR.
 Minimal acceptance requirements of sensitivity and specificity of Speedy Ag Verify Kits:
 Validated as a Stage of Care Verify (POCT) with out transport to a laboratory setupSensitivity: 50% and above; Specificity: 95% and above
 Validated in a laboratory setup with samples collected in Viral Transport Medium (VTM)- Sensitivity: 70% and above; Specificity: 99% and above
 Antigen based totally speedy assessments which might be US-FDA permitted will be utilized instantly after due promoting and advertising approval from DCGI.

In June 2020, JOYSBIO Biotechnology proudly launched a model new COVID-19 Antigen Speedy Verify Tools (Colloidal Gold). The model new coronavirus antigen check out gear is a lateral transfer immunoassay for the qualitative detection of SARS-COV-2 antigen (nucleocapsid protein) in larger respiratory samples with nasal swabs or saliva in the midst of the acute part of an an infection. An uncut sheet format is on the market.

Choices

• 15-minute speedy detection
• Simple-to-operate coronavirus antigen check out
• A lot less-invasive nasal (NS) swab sample assortment
• CE-IVD marked
• Accessible in half/5/20 assessments/subject.

Abstract

Background

The Coronavirus sickness 2019 (COVID-19) pandemic continues to unfold internationally. Due to this fact, there’s an urgent need for fast, straightforward, and proper assessments to diagnose excessive acute respiratory syndrome coronavirus 2 (SARS-CoV-2) an an infection. Effectivity traits of the speedy SARS-CoV-2 antigen detection check out must be evaluated and in distinction with the gold customary real-time reverse transcription-polymerase chain response (RT-PCR) check out for prognosis of COVID-19 situations.

Methods

The speedy SARS-CoV-2 antigen detection check out, Customary Q COVID-19 Ag gear (SD Biosensor®, Republic of Korea), was in distinction with the real-time RT-PCR check out, Allplex 2019-nCoV Assay (Seegene®, Korea) for detection of SARS-CoV-2 in respiratory specimens. Four hundred fifty-four respiratory samples (primarily nasopharyngeal and throat swabs) had been obtained from COVID-19 suspected situations and converse to folks, along with pre-operative victims at Siriraj Hospital, Bangkok, Thailand all through March–Would possibly 2020.

Outcomes

Of 454 respiratory samples, 60 (13.2%) had been constructive, and 394 (86.8%) had been detrimental for SARS-CoV-2 RNA by real-time RT-PCR assay. The size from onset to laboratory check out in COVID-19 suspected situations and converse to folks ranged from Zero to 14 days with a median of three days. The speedy SARS-CoV-2 antigen detection check out’s sensitivity and specificity had been 98.33% (95% CI, 91.06–99.96%) and 98.73% (95% CI, 97.06–99.59%), respectively. One false detrimental check out consequence was from a sample with a extreme real-time RT-PCR cycle threshold (Ct), whereas 5 false constructive check out outcomes had been from specimens of pre-operative victims.

Melamine Rapid Test Kit
abx092011-50tests	Abbexa	50 tests	EUR 444

Human Streptococcus Pneumoniae (SP) Antigen Rapid Test Kit
abx092096-20tests	Abbexa	20 tests	EUR 477.6

SARS-CoV-2 Rapid Antigen Test Nasal
9901-NCOV-03G	Roche Diagnostics	25 Tests/Kit	EUR 112.8
Description: The SARS-CoV-2 Rapid Antigen Test is a lateral fl ow rapid chromatographic immunoassay for the qualitative detection of nucleocapsid antigen to SARS-CoV-2 present in human nasal samples. This test is intended for use as an aid in detection of SARS-CoV-2 infection in individuals suspected of COVID-19 with clinical symptoms onset within 5 days. Results are for the identification of SARS-CoV-2 nucleocapsid antigen. Antigen is generally detectable in human nasal swab samples during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co- infection with other viruses. The agent detected may not be the definite cause of disease. Negative results should be treated as presumptive, and do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19, and confirmed with a molecular assay, if necessary, for patient management. The SARS-CoV-2 Rapid Antigen Test is intended for use in laboratory or POC settings by healthcare professionals, or self-collection under the supervision of a healthcare worke

Avian Influenza Virus Antigen Rapid Test Kit (Colloidal gold)
abx092015-40tests	Abbexa	40 tests	EUR 518.4

Newcastle Disease Virus Antigen Rapid Test Kit (Colloidal gold)
abx092016-40tests	Abbexa	40 tests	EUR 518.4

Human Chlamydia Trachomatis Antigen Rapid Test Kit (Colloidal gold)
abx092049-20tests	Abbexa	20 tests	EUR 276

Melamine (MEL) Rapid Test Kit
abx092057-50tests	Abbexa	50 tests	EUR 444

Clenbuterol (CLE) Rapid Test Kit
abx092058-50tests	Abbexa	50 tests	EUR 292.8

Ractopamine (RAC) Rapid Test Kit
abx092059-50tests	Abbexa	50 tests	EUR 292.8

Salbutamol (SAL) Rapid Test Kit
abx092060-50tests	Abbexa	50 tests	EUR 292.8

Tetracycline (TCs) Rapid Test Kit
abx092063-50tests	Abbexa	50 tests	EUR 477.6

Sulfonamides (Sas) Rapid Test Kit
abx092064-40tests	Abbexa	40 tests	EUR 477.6

Quinolones (QNs) Rapid Test Kit
abx092065-40tests	Abbexa	40 tests	EUR 477.6

Ciprofloxacin (CPFX) Rapid Test Kit
abx092066-50tests	Abbexa	50 tests	EUR 477.6

Quinolones (QNs) Rapid Test Kit
abx092067-40tests	Abbexa	40 tests	EUR 477.6

Brucella Antibody Rapid Test Kit
abx092069-40tests	Abbexa	40 tests	EUR 427.2

Accu-Tell COVID-19 IgG/IgM Rapid Test
GEN-B352-20tests	Accu test	20 tests	EUR 283.2
Description: A rapid test for detection of antibodies (IgG and IgM) for 2019-nCoV, the novel Coronavirus from the Wuhan strain. The test is easy to perform, takes 10 minutes to provide reliable results and is higly specific to the 2019-nCoV Coronavirus.

Accu-Tell COVID-19 IgG/IgM Rapid Test
GEN-B352-40tests	Accu test	40 tests	EUR 385.2
Description: A rapid test for detection of antibodies (IgG and IgM) for 2019-nCoV, the novel Coronavirus from the Wuhan strain. The test is easy to perform, takes 10 minutes to provide reliable results and is higly specific to the 2019-nCoV Coronavirus.

Avian Influenza H5 Virus Antigen Rapid Test Kit (Colloidal gold)
abx092014-40tests	Abbexa	40 tests	EUR 585.6

Avian Influenza H7 Virus Antigen Rapid Test Kit (Colloidal gold)
abx092017-40tests	Abbexa	40 tests	EUR 518.4

Coronavirus (SARS-Cov-2) Antigen Rapid Test Device (Saliva)
IOV87952	INVBIO	20T/kit	EUR 46.8
Description: Coronavirus (SARS-Cov-2) Antigen Rapid Test Device (Saliva) is an in vitro diagnostic test for the qualitative detection of novel coronavirus antigens in human saliva, using the rapid immunochromatographic method. The identification is based on the monoclonal antibodies specific for the novel coronvirus antigen. It will provide information for clinical doctors to prescribe correct medications.

Clenbuterol Rapid Test Kit (Colloidal gold)
abx092040-50tests	Abbexa	50 tests	EUR 326.4

Ractopamine Rapid Test Kit (Colloidal gold)
abx092042-50tests	Abbexa	50 tests	EUR 360

Salbutamol Rapid Test Kit (Colloidal gold)
abx092043-50tests	Abbexa	50 tests	EUR 410.4

Chloramphenicol Rapid Test Kit (Colloidal gold)
abx092045-50tests	Abbexa	50 tests	EUR 427.2

Quinolones Rapid Test Kit (Colloidal gold)
abx092046-50tests	Abbexa	50 tests	EUR 644.4

Sulfonamides Rapid Test Kit (Colloidal gold)
abx092047-50tests	Abbexa	50 tests	EUR 661.2

×